Seelig G F, Prosise W W, Scheffler J E
Schering-Plough Research Institute, Kenilworth, New Jersey 07033-0539.
J Biol Chem. 1994 Feb 25;269(8):5548-53.
A synthetic segment (110-127) of the carboxyl terminus of recombinant human granulocyte-macrophage colony-stimulating factor (rh-GM-CSF) was used to generate a rabbit polyclonal antibody (345-6), which recognized both peptide and full-length Escherichia coli-derived rh-GM-CSF in a direct enzyme-linked immunosorbent assay. Antibody 345-6 was shown to antagonize the binding of 125I-labeled rh-GM-CSF to its receptor on the KG-1 cell line and to inhibit human GM-CSF-dependent proliferation of the AML-193 cell line. The purified IgG fraction of neutralizing antibody 345-6 was used as immunogen to obtain sheep anti-serum 1418. Antibody 1418 recognized antibody 345-6 on direct enzyme-linked immunosorbent assay but did not recognize rh-GM-CSF or the peptide 110-127 to which antibody 345-6 was raised. Antiserum 1418, as well as a purified IgG fraction of this serum, inhibited both rh-GM-CSF-stimulated cell proliferation and 125I-labeled rh-GM-CSF receptor binding but not 125I-labeled recombinant human interleukin-4 receptor binding. The anti-idiotypic antibody response derived from the anti-(110-127) antibody strongly suggests that the carboxyl-terminal region of rh-GM-CSF may be directly involved in the receptor-ligand interaction of this protein. The high affinity receptor consists of two different components (GM-R alpha beta) a cytokine-specific alpha-subunit and a beta-subunit that is shared by human GM-CSF, interleukin-3, and interleukin-5. In an effort to localize the epitope of antibody 1418 to either GMR alpha or GMR beta, several cell lines containing high, low, or both high and low affinity receptors were examined. Each was specifically and completely inhibited by antibody 1418. Interleukin-3-dependent cell proliferation of the AML-193 cell line was found to be unaffected by the antibody 1418. Thus, the carboxyl-terminal region of rh-GM-CSF is likely to be involved in the interaction of the ligand with the alpha-subunit of the high affinity receptor.
重组人粒细胞巨噬细胞集落刺激因子(rh-GM-CSF)羧基末端的合成片段(110-127)用于制备兔多克隆抗体(345-6),该抗体在直接酶联免疫吸附测定中可识别肽段和全长大肠杆菌来源的rh-GM-CSF。抗体345-6可拮抗125I标记的rh-GM-CSF与其在KG-1细胞系上的受体结合,并抑制AML-193细胞系的人GM-CSF依赖性增殖。将中和抗体345-6的纯化IgG组分用作免疫原,以获得羊抗血清1418。抗体1418在直接酶联免疫吸附测定中可识别抗体345-6,但不能识别rh-GM-CSF或抗体345-6所针对的肽段110-127。抗血清1418及其纯化的IgG组分均可抑制rh-GM-CSF刺激的细胞增殖和125I标记的rh-GM-CSF受体结合,但不抑制125I标记的重组人白细胞介素-4受体结合。源自抗(110-127)抗体的抗独特型抗体反应强烈表明,rh-GM-CSF的羧基末端区域可能直接参与该蛋白的受体-配体相互作用。高亲和力受体由两种不同成分(GM-Rαβ)组成,一种是细胞因子特异性α亚基,另一种是β亚基,人GM-CSF、白细胞介素-3和白细胞介素-5共享该β亚基。为了将抗体1418的表位定位到GMRα或GMRβ上,检测了几种含有高亲和力、低亲和力或同时含有高亲和力和低亲和力受体的细胞系。每种细胞系均被抗体1418特异性且完全抑制。发现AML-193细胞系的白细胞介素-3依赖性细胞增殖不受抗体1418影响。因此,rh-GM-CSF的羧基末端区域可能参与配体与高亲和力受体α亚基的相互作用。